Zhang Qi-Zhou, Li Yu-Bin, Yilihamu Nazi, Li Xiao-Hong, Ba Ya, Qin Yong-De
Department of Nuclear Medicine, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Front Chem. 2022 Apr 12;10:826678. doi: 10.3389/fchem.2022.826678. eCollection 2022.
Based on the Tracerlab FX platform, a synthesis program and preparative high-performance liquid chromatography (HPLC) purification program edited by us can stably and repeatedly produce [F] AV-45 without changing the process. The [F] AV-45 produced meets the main indexes of radiopharmaceutical intravenous preparations. The O-toluene sulfonated precursor (1 mg) was subjected to nucleophilic radiofluorination at 115°C in anhydrous dimethyl sulfoxide (DMSO), then the protective group was hydrolyzed by acid. The neutralized reaction mixture was purified through a preparative HPLC then formulated for injection using a C18 purification cartridge. This method yielded a relatively pure [F] AV-45 product with high specific activity. Four consecutive radiochemical synthesis operations were carried out in this experiment; the average production time of [F] AV-45 preparation was 60 min, the radiochemical yield was 14.8 ± 2.1% ( = 4), the radiochemical purity was greater than 95%, and the other important quality control indexes met the requirements of radioactive drugs for intravenous administration. This experiment was based on the Tracerlab FX platform with the synthesis program and preparative HPLC purification program edited by us. Through screening and optimization of the separation and purification system and the separation and analysis system, as well as automatic radiochemical synthesis and preparation quality control, intravenous [F] AV-45 was successfully prepared.
基于Tracerlab FX平台,我们编辑的合成程序和制备型高效液相色谱(HPLC)纯化程序可在不改变工艺的情况下稳定且重复地生产[F]AV-45。所生产的[F]AV-45符合放射性药物静脉制剂的主要指标。将邻甲苯磺酰化前体(1毫克)在115°C的无水二甲基亚砜(DMSO)中进行亲核放射性氟化反应,然后用酸水解保护基团。将中和后的反应混合物通过制备型HPLC进行纯化,然后使用C18纯化柱配制注射剂。该方法得到了具有高比活度的相对纯的[F]AV-45产品。本实验连续进行了4次放射化学合成操作;[F]AV-45制剂的平均生产时间为60分钟,放射化学产率为14.8±2.1%(=4),放射化学纯度大于95%,其他重要的质量控制指标符合静脉注射放射性药物的要求。本实验基于Tracerlab FX平台,采用我们编辑的合成程序和制备型HPLC纯化程序。通过对分离纯化系统和分离分析系统的筛选与优化,以及放射化学合成与制剂质量的自动控制,成功制备了静脉注射用[F]AV-45。